Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mibavademab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Mibavademab - Regeneron Pharmaceuticals

Alternative Names: REGN-4461

Latest Information Update: 09 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action Leptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lipodystrophy; Obesity
  • Phase II Amenorrhoea

Most Recent Events

  • 27 Mar 2026 Phase-III clinical trials in Lipodystrophy (In infants, In children, In adolescents, In adults, In the elderly) in USA (IM) (NCT07220785) (CTIS-2024-519879-25-00)
  • 27 Mar 2026 Regeneron Pharmaceuticals initiates enrolment in a phase III trial for Lipodystrophy (In infants, In children, In adolescents, In adults, In the elderly) in the US (IV) (NCT07220785) (CTIS-2024-519879-25-00)
  • 27 Mar 2026 Regeneron Pharmaceuticals initiates enrolment in a phase III trial for Lipodystrophy (In infants, In children, In adolescents, In adults, In the elderly) in the US (SC) (NCT07220785) (CTIS-2024-519879-25-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top